英文简介
1
Long-Hua Chen Professor
Chief Physician, Professor,
|
||
Chair,
Honorary Chair,
|
||
Brian O’Sullivan MD, FRCPC, FRCPI, FFRRCSI (Hon), FASTRO |
||
Brian O’Sullivan is a Professor in the Department of Radiation Oncology and the Department of Otolaryngology / Head and Neck Surgery at the University of Toronto, Toronto, Ontario, Canada. He works at the Princess Margaret Hospital (PMH), a Teaching Hospital of the University of Toronto, Toronto, Canada. He graduated from University College Dublin, Ireland in 1976, and completed a fellowship in medical oncology, a residency and clinical fellowship in radiation oncology, all at PMH. A past President of the Connective Oncology Society (CTOS) and former Head of both the Sarcoma and H&N Oncology Programs at PMH, is the radiation oncology Chair of the US NCI Head and Neck Steering Committee. He now Leads the Princess Margaret Hospital – University of Hong Kong / Shenzhen Hospital Radiation Oncology Sanming project in China. He has published almost 400 peer-reviewed papers, numerous additional manuscripts, more than 100 invites book chapters and manuscripts, and written or edited 10 oncology textbooks. He is a member of the TNM Committee of the Union for International Cancer Control (UICC), Chair of the UICC Prognostic Factors Sub-Committee and is UICC head and neck cancer and soft tissue / bone sarcoma liaison to the American Joint Committee on Cancer (AJCC). He is one of three clinicians who are Commissioners of the ICRU.
|
||
Anne W. M. LEE
|
||
Prof. Anne Lee is currently the Clinical Professor and Head, Department of Clinical Oncology, The University of Hong Kong. In addition, she is Deputy Hospital Chief Executive (Clinical Services) at the University of Hong Kong-Shenzhen Hospital and Chief of Service for the Center of Clinical Oncology at the University of Hong Kong-Shenzhen Hospital in China. She is also the Honorary Consultant and Deputy Chief of Service of Clinical Oncology Departments of Clinical Oncology at Queen Mary Hospital in Hong Kong and Honorary Professor at Peking Union Medical College Hospital.
|
||
Feng-Ming (Spring) Kong |
||
Professor of Clinical Oncology Hong Kong University, Hong Kong University SZH
(2013-2016)
|
||
Lvhua Wang
Professor of Radiation Oncology
|
||
Expertise: Clinical research on radiation therapy for thoracic cancers, Radiation-induced lung toxicity, translational research on genetics of lung cancer Achievement: Promoting IMRT technology of thoracic cancer in China, improving the key techniques for standardized treatment of lung and esophageal carcinoma. Published Articles: Over 50 peer-reviews articles, including Journal of clinical oncology, Annals of oncology. Awards:
|
||
Weixi Shen M. D., Ph. D of Oncology, Cancer Hospital Peking Union Medical College
Chinese Academy of Medical Sciences Shenzhen People’s Hospital |
||
President, Shenzhen Anti-cancer Association.
|
||
Chunxue Bai
MD, PhD Zhongshan Hospita,Fudan University |
||
Professor Chunxue Bai was trained at Beijing Union Medical College and Shanghai Medical University. He was a Postdoctoral Research Fellow at University of California, San Francisco, from 1997 to 1998. He is the Director of Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University. He serves as Chair of Chinese Alliance against Lung Cancer (CALC), President of Chinese Society of e-Health and Chair of Research Committee for APSR. He was the congress President of APSR 2011.
His major scientific contributions are the understanding of pathogenesis of and therapies for He established Chinese Alliance Against Lung Cancer (CALC) in 2012 and launched a campaign of HTH with opening hundred sub-centers, educating thousand specialists for diagnosis and with aim to treat hundred thousand cases of early stage lung cancer from pulmonary nodules each year. He is known for his pioneering work of e-health and his cell phone-based remote monitoring system for lung function and has been included in Who’s Who at ATS. His other achievements including advocacy, teaching, and the exceptional contribution of launching China Day at ATS, ERS, WCLC and APSR with the words "open to the world, become international".
|
||
Jing CAI PhD DABR FAAPM |
||
Fellow of AAPM
|
||
Laura Dawson |
||
Dr Laura Dawson is a radiation oncologist at the Princess Margaret Cancer Centre, and a Professor the Department of Radiation Oncology, University of Toronto. She completed her medical school and radiation oncology residency at the University of Toronto and a fellowship in high precision radiation therapy at the University of Michigan, where she stayed on as a faculty member until 2003, at which time she returned to Canada to develop a hepatobiliary radiation therapy program at the Princess Margaret Cancer Centre. She is an internationally recognized leader in hepatobiliary cancers and liver metastases and in the use of advanced radiation technologies, including stereotactic body radiation therapy (SBRT) and image guided radiation therapy (IGRT). She is the principal investigator of several phase III clinical trials, including RTOG1112, an international randomized trial of SBRT for locally advanced hepatocellular carcinoma and HE.1, a Canadian randomized trial of low dose whole liver radiation therapy to treat painful primary and metastatic liver cancers. She has published over 150 scientific papers. She was a recipient of an ASCO career development award, and her research has been funded by the NIH, CIHR, NCIC CTG, and the Canadian Cancer Society.
|
||
Chen Hu
PhD in biostatistics from the University of Michigan, Ann Arbor
|
||
Assistant Professor, Johns Hopkins University
|
||
Jian-Dong Huang
Ph.D.
|
||
L & T Charitable Foundation Professor in Biomedical Sciences School of Biomedical Sciences, Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR, P.R. China Organized domestic and international academic conferences, including the International Conference on Synthetic Biology (SB4.0, SB5.0). More than 50 invitation reports at home and abroad
|
||
Sophie (Shao Hui) Huang
Assistant Professer, M.R.T (T), MSc, MD
|
||
Brief Description of Responsibilities:
Educational Preparation: B.Sc (Hons), Radiation Science (Radiation Therapy)
|
||
Paula M. Jacobs |
||
Paula M. Jacobs, PhD, joined NCI after 30 years in the pharmaceutical and medical device industries, where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. She became Deputy Associate Director of DCTD responsible for CIP in 2009, Associate Director in 2011, and Expert Advisor in 2018. Her efforts for NCI have been focused on lowering the scientific, logistical, and regulatory barriers to investigational use of positron emission tomography radiopharmaceuticals for therapeutic drug development by facilitating access to Investigational New Drug (IND) filings and by overseeing research to develop labeled drugs for clinical and preclinical use, particularly for optical imaging agents used to assist surgeons to make complete resections. Another effort is focused on wide-ranging aspects of standardization and quantitative imaging techniques, and a third focus is on genome-imaging correlations. Dr. Jacobs serves on three NCI Experimental Therapeutics (NExT) committees to review and manage the projects chosen for development. She oversees a radiochemistry laboratory and radioactive drug production facility at the Frederick National Laboratory for Cancer Research that provides preclinical and early clinical radiopharmaceuticals in support of therapeutic drug development. Her industrial experience began at Clinical Assays, a division of Baxter Travenol that manufactured in vitro radioimmunoassays, where she was responsible for process improvements in radioactive tracer synthesis, technical product maintenance, product and process improvements, and manufacturing of all reagents used in the company’s products. At Seragen, a small biotechnology firm, she was General Manager, with profit and loss responsibility for a division that developed, manufactured, and marketed prostaglandin, leukotriene, and small protein immunoassays. Subsequently she joined Advanced Magnetics as Vice President, Development, to help chart a new course for this small biomedical products company. She was responsible for the development of iron oxide magnetic contrast agents from laboratory synthesis through IND submissions, including design of pharmacology, toxicology, and clinical studies. She served as international liaison for technology transfer to licensees, worked with independent physicians in the United States and abroad to develop physician IND trials in magnetic resonance imaging, and collaborated with academic researchers in a variety of preclinical investigations. Dr. Jacobs has published papers in the areas of organic chemistry, inorganic chemistry, magnetic resonance imaging, positron emission tomography, neuro-oncology, and nephrology.
|
||
Jian-Yue (JJ) Jin PhD |
||
Professor, Director of Medical Physics and Dosimetry, Radiation Oncology, Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA
|
||
Allen Li
Ph.D |
||
Dr. X. Allen Li is a tenured professor and the Chief of Medical Physics in the Department of Radiation Oncology, Medical College of Wisconsin. He has over 25-years of experience in developing methodologies and technologies to improve radiation therapy for cancer. Areas of his research covers adaptive radiation therapy, MRI-guided radiation therapy, quantitative imaging for radiation response assessment, and radiation outcome modeling for radiation treatment planning. In last five years, his research focus is on MR-guided adaptive radiation therapy. He has been frequently invited, for more than 100 times, to speak nationally and internationally on these topics. Dr. Li's bibliography includes more than 200 peer-reviewed papers, one textbook, 13 book chapters, and nearly 400 conference abstracts. He was the principal investigator for over 30 projects funded by federal or private agencies and co-investigator for 20 funded research projects. Dr. Li has served as a grant peer reviewer for more than 10 funding organizations and as an associate editor or peer reviewer for 18 scientific journals. He is a Fellow of AAPM, and the current president for Sino-American Network for Therapeutic Radiology and Oncology (SANTRO).
|
||
Zihai Li
MD, PhD |
||
Elected Member of The American Association of Physicians
|
||
Hui Liu MD, PhD |
||
Professor, Chief of Thoracic Service, Deputy Chair/Medical Director of Department of Radiation Oncology, Sun Yat-sen University Cancer Center
|
||
Doug Moseley
PhD |
||
Dr. Doug Moseley completed his PhD in the Department of Applied Mathematics at the University of Western Ontario, London, Ontario in 1995. After 7 years with Honeywell’s Industrial Automation and Control Division in Phoenix AZ, he returned to Canada in 2001. Doug transitioned to a small bio-medical startup company before landing in the Radiation Therapy Physics department at Princess Margaret Cancer Centre in 2002. He is an Assistant Professor in the University of Toronto’s Department of Radiation Oncology. Since 2008, Doug has been the Deputy Chief of Medical Physics at the Stronach Regional Cancer Centre at Southlake. His current research interests focus on the development of novel image processing techniques as well as the use of image-guidance with cone-beam CT for radiation therapy delivery. Dr. Moseley received the 2012 U of T Colin R. Woolf Award for Excellence in Continuing Education Teaching. He is currently certified in Therapeutic Radiologic Physics by the American Board of Radiology.
|
||
Juwei Mu
MD |
||
Deputy Chief of Thoracic Surgery Department, National Cancer Center, CHCAMS
|
||
Wai Tong Ng
MD |
||
Dr. Ng received his medical school training at the Chinese University of Hong Kong. Upon completion of his internship training, Dr. Ng joined the Department of Clinical Oncology at Prince of Wales Hospital in 1992 and later Pamela Youde Nethersole Eastern Hospital in 1994. He attained Fellow of the Royal College of Radiologists in 1997 and was conferred Doctor of Medicine at the University of Hong Kong in 2008. Dr. Ng is currently consultant at the Pamela Youde Nethersole Eastern Hospital, honorary clinical associate professor at the University of Hong Kong, honorary clinical associate professor at the Chinese University of Hong Kong, and past president of the Hong Kong Head and Neck Society. He also serves the editorial board of Oral Oncology and Journal of Hong Kong College of Radiologists, and is also a member of TNM Expert Advisory Panel on Head and Neck Cancers for the UICC. Over the years, Dr. Ng has been actively engaged in clinical research and has contributed to more than 100 publications. His main interest is head and neck oncology.
|
||
Daniel A. Pryma
Associate Professor of Radiology & Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania |
||
Daniel A. Pryma, MD is Associate Professor of Radiology & Radiation Oncology at the Perelman School of Medicine at the University of Pennsylvania. He is Chief of the Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology and is co-Leader of the Radiobiology & Imaging Program of the Abramson Cancer Center at the University of Pennsylvania. He is the Past Chair of the American Board of Nuclear Medicine and the President of the Therapy Center of Excellence of the Society of Nuclear Medicine & Molecular Imaging. His research focuses on pre-clinical, translational and clinical testing of therapeutic radiopharmaceuticals, companion diagnostics and image guided therapy. He has led both local and multi-center trials and is the Chair of the Imaging Committee of NRG Oncology.
|
||
Jin-Xiong She
PhD |
||
Jin-Xiong She, PhD received his college education in China and PhD degree in France. After a short postdoctoral training, he was quickly promoted to Assistant Professor, Associate Professor, Full and Endowed Professor at the University of Florida (UF). He served as Division Chief of Experimental Pathology and Director of Research of the UF’s Diabetes Center. Dr. She was recruited in 2002 to be the Georgia Research Alliance Eminent Scholar in Genomic Medicine at the Medical College of Georgia. He is also the founding and current Director of the Center for Biotechnology and Genomic Medicine and Professor, Department of Obstetrics and Gynecology as well as the director of two core research facilities for Augusta University and the Georgia Research Alliance: Genomics, and Proteomics & Mass Spectrometry. In his academic career, he has authored over 300-peer reviewed papers with an H-Index of 57 and over 10,000 citations, secured over $100 million in research grants, invited to speak globally. He mentored 13 doctoral students, 47 post-docs and 12 faculty. Dr. She is one of the top 20 “Georgia Top Medical Researchers” name by the Atlanta Business Chronicle. He served as President of the Chinese Geneticists in America and President of the American Diabetes Association’s council on Immunology, transplantation and Immunogenetics among other honors. Dr. She is a serial entrepreneur and has founded or co-founded six companies, the latest of which is Jinfiniti Precision Medicine, Inc. that aims to provide a one-stop shop for precision oncology services focusing on early diagnosis, genetic testing and drug sensitivity testing.
|
||
Geng Tian
MD |
||
Winner of Outstanding Young Scientist Award of Science Chinese in 2015
|
||
王健 毕业于中南大学湘雅医学院 |
||
暨南大学第二临床医学院深圳市人民医院胸外科、副主任医师、医学硕士 广东省胸部肿瘤防治研究会机器人与微创外科专业委员会委员 广东省胸部疾病学会胸壁外科专业委员会委员 广东省生物医学工程学会胸心外科分会委员 广东省医师协会胸外科医生分会第二届委员会食管癌专业组组员 吴阶平基金会模拟医学部胸外科专委会委员 深圳市医学会胸外科专业委员会委员 深圳市抗癌协会肺癌专业委员会委员 深圳市医师协会胸部肿瘤分会理事 Up To Date 临床顾问
|
||
王岩 副主任医师 博士 |
||
毕业于哈尔滨医科大学,从事临床病理诊断工作十余年,亚专业方向为胸肺部病理诊断。作为主要负责人承担国家级科研项目一项,省级课题三项,发表SCI文章5篇,国家级文章十余篇。
|
||
Huanmei Wu
Chair of BioHealth Informatics, School of informatics and Computing, |
||
Chair, Department of BioHealth Informatics
|
||
Yi-Long Wu Professor of Oncology,PhD Turtor, Winner of Outstanding Science Achievement from IASLC |
||
Director (Tenured) of Guangdong General Hospital
|
||
Heng Xie |
||
Heng Xie is the Chief Medical Officer at Shenzhen Salubris Pharmaceuticals Co., Ltd. and a senior adviser to the Mayo Clinic Cancer Center, China National Cancer Center, China National Center of Biomedical Analysis, China Health Promotion Foundation and the national editorial committee for Chinese dictionary of oncology. In addition, Dr. Xie is a member of the editorial board of “Cancer Biomarkers”and “Translational Cancer Research”.
|
||
Yaoqin Xi
PHD
|
||
Associate Editor of Medical Physics
|
||
Jinming Yu Professor, Shandong Cancer Hospital CAE academician, M.D, Ph.D Tutor |
||
Member of Standing Committee of Shandong Province People's Congress
|
||
Shuanghu(Tiger) Yuan MD,PHD |
||
Professor and Chair of Thoracic Radiaiton Oncology Department at Shandong Cancer Hospital & Institute
|
||
Weining Ken Zhen
MD |
||
Professor and Medical Director of Radiation Oncology
|
||
Lei Zheng
M.D., Ph.D. |
||
Lei Zheng, M.D., Ph.D. is an associate professor of Oncology and Surgery in the Gastrointestinal Oncology Program at the Johns Hopkins University School of Medicine and lead a large translational program that focuses on the preclinical and clinical development of novel vaccine- and antibody-based rational combination immunotherapy for gastrointestinal cancers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is Director of the Pancreatic Cancer Precision Medicine Program, a Pancreatic Cancer Center of Excellence at Johns Hopkins and Leader of Personalized Medicine Program at the Bloomberg-Kimmel Institute for Cancer Immunotherapy. His clinical work is focused on multidisciplinary management for pancreatic cancer, bile duct cancer, liver metastases, and gastric cancer. In addition, he is a lead researcher in the group of Johns Hopkins Cancer Center’s physician scientists who have developed the pancreatic cancer GVAX vaccine and are currently leading eight investigator-initiated clinical trials of checkpoint inhibitor-based combination immunotherapy. More recently, his laboratory started to develop neoantigen-based vaccines and nanoparticle based adjuvant systems. He has also applied his knowledge gained from pancreatic cancer immune-based therapies to the development of a colorectal cancer vaccine and to the development of immunotherapy for bile duct cancer. He is affiliated with the Tumor Immunology Program as a laboratory investigator and possesses a large clinical trial associated biospecimen bank. His primary laboratory research focus is on the identification of new targets for pancreatic cancer therapies by dissecting tumor microenvironment of pancreatic cancer. Since 2013, he has published over 70 peer-reviewed papers and given more than 30 plenary and keynote speeches in national and international symposia. He is the founding Editor-in-Chief of Annals of Pancreatic Cancer, the only scientific journal that is solely focused on the malignant diseases of the pancreas. He is President of the Chinese American Hematologist and Oncologist Network (CAHON).
|